Calliditas Therapeutics AB (publ) (CALT)

Market Cap	498.61M
Revenue (ttm)	105.88M
Net Income (ttm)	-26.91M
Shares Out	26.84M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	8.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,761
Open	18.68
Previous Close	18.27
Day's Range	17.70 - 19.00
52-Week Range	10.82 - 25.64
Beta	1.34
Analysts	Strong Buy
Price Target	49.00 (+163.72%)
Earnings Date	Nov 13, 2023

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 169
• Stock Exchange: NASDAQ
• Ticker Symbol: CALT

Financial Performance

In 2022, CALT's revenue was 802.88 million, an increase of 250.07% compared to the previous year's 229.35 million. Losses were -412.27 million, -17.59% less than in 2021.

Financial numbers in SEK

Analyst Forecast

According to 3 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is $49.0, which is an increase of 163.72% from the latest price.

Price Target

$49.0

(163.72% upside)

Analyst Consensus: Strong Buy